Treating bone weakness in Werner syndrome
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an investigational drug for people with Werner syndrome who have weak bones (osteopenia or osteoporosis). The goal is to see if the drug is safe and can help improve bone health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of Werner syndrome through genetic testing.
- You must have low bone density (osteopenia or osteoporosis).
- You must be willing to use birth control during the study and for 90 days after treatment.
- You must be able to follow study procedures and give written consent.
- You must not have had treatment with an experimental drug within the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well your blood vessels work and how strong your muscles are, in women after menopause with osteoporosis. You may be asked to start standard osteoporosis treatment, and the researchers will study pain and changes related to vascular function and sarcopenia (loss of muscle and strength).
This trial tests a drug that may help older people who break a hip and have low muscle mass (sarcopenia). It aims to see if the drug can help preserve muscle strength and speed up recovery after surgery.
This trial tests whether combining resistance training with the drug rapamycin can improve bone formation in postmenopausal women who have lower-than-normal bone density but not osteoporosis. It aims to find a new way to strengthen bones and prevent fractures.
This trial studies AGN1 LOEP, a treatment being tested to improve bone strength in people with osteoporosis-related bone loss in the hip. If you qualify, you would be followed over time with clinic visits and testing to see how the treatment affects your bone health.
This trial tests a new drug called AGA2115 for people with osteogenesis imperfecta (also known as brittle bone disease) who have a confirmed genetic change in the COL1A1 or COL1A2 genes. The study aims to see if the drug can help strengthen bones and reduce fracture risk.
This trial tests a new medication called PTH-IA for people with a specific genetic mutation affecting the parathyroid hormone receptor. The study aims to see if the medication is safe and can help improve bone health in children and adults with this rare condition.
Hear when a new Werner Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.